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the influence of hypoxia and/or the TAM phenotype. In
sum, we have identified a set of novel key molecules that
dictate the TAM phenotype during tumor growth.
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In hematopoietic cells, serglycin proteoglycans mainly
contribute to proper storage and secretion of inflammatory
mediators via their negatively charged glycosaminogly-
cans. In cancer cells serglycin proteoglycans are also
expressed in close association with the cell surface marker
CD44, where increased expression of serglycin has been
linked to poor prognosis. We recently reported that
genetic ablation of serglycin completely blocked lung
metastasis in the MMTV-PyMT-driven mouse breast
cancer model, while serglycin-deficiency did not affect
primary tumour growth or number of mammary tumours.
In the primary tumours CCL2 expression indicated equal
levels of inflammation, whereas numbers of tumour-
associated mast cells were reduced in the serglycin-
deficient mice. A microarray expression analysis and
functional annotation of differentially expressed genes in
primary tumour tissue identified several biological path-
ways where serglycin may be important. Although E-
cadherin expression was higher in the serglycin-deficient
primary tumour tissue, indicating reduced invasiveness,
serglycin-deficient tumour cells were still detected in the
circulation. Primary tumour cells (SG+/ and SG/) have
been established in cell culture, where we investigate the
role for serglycin in migration and extravasation with
CRISPR/Cas9 mediated knockdown. In addition, when the
primary mouse tumour cells were injected i.v. in SG-
competent and SG-deficient mice injected SG/ tumour
cells failed metastasis to the lung. Our results suggest that
serglycin proteoglycans play an essential role in extrava-
sation of metastatic cells, and that serglycin and serglycin-
dependent mediators are potential drug targets to prevent
metastatic disease/dissemination of cancer. We now aim to
identify the serglycin-dependent mediators promoting
metastasis and define their role.
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Cellular endothelial transmigration is an important process
whereby cells exit the circulatory system and invade
surrounding tissues, key to normal immune system
function and cancer metastasis. During normal leukocyte
behaviour, the circulatory system enables leukocytes to
patrol the body, searching for infections and physical
damage. Upon encountering cues indicative of these
situations, leukocytes will exit the circulatory system
through the vessel wall and enter the surrounding tissue.
Cancer metastasis is the process during which cancer cells
leave the primary tumour, move through the surrounding
tissue and enter the vascular system. The cancer cells will
travel through the vascular system and eventually cross the
blood vessel walls and establish new tumours in the
surrounding tissue, with detrimental consequences to the
patients. The mechanisms involved in these processes are
inadequately understood and current knowledge relies
heavily on cumbersome animal experiments and non-
physiological in vitro models. The aim of this project is to
adopt, adapt and improve microfluidic blood vessel models
for use in our lab in order to create more reliable in vitro
conditions to study leukocyte and cancer cell extravasation,
thus reducing the number of animal experiments needed.
So far, we have established a lab for manufacturing and
operating microfluidic devices and currently we are testing
suitable device designs for our extravasation studies.
*Shared first-authorship
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Recent studies are encouraging research of breast cancer
immunogenicity to evaluate the applicability of
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immunotherapy as a treatment strategy. The epitope
landscape in breast cancer is minimally described, thus it
is necessary to identify T cell targets to develop immune
mediated therapies.
This project investigates four proteins commonly upreg-
ulated in breast cancer and thus probable tumor associated
antigens (TAAs). Aromatase, prolactin, NEK3, and PIAS3
contribute to increase growth, survival, and motility of
malignant cells. Aspiring to uncover novel epitopes for
cytotoxic T cells, a reverse immunology approach is
applied. Via in silico screening of the protein sequences,
415 peptides were predicted as HLA-A*0201 and HLA-
B*0702 binders. Subsequent in vitro binding analysis in a
MHC ELISA platform confirmed binding for 147 of the
415 predicted binders. The 147 peptides were evaluated for
T cell recognition utilizing DNA barcode labeled MHC
multimers to screen peripheral blood lymphocytes from
breast cancer patients and healthy donor samples. Signif-
icantly more TAA specific T cell responses were detected in
breast cancer patients than healthy donors for both HLA-
A*0201 (P < 0.0039) and HLA-B*0702 (P < 0.001)
restricted peptides. Importantly, several of the identified
responses were toward peptides that were predicted as poor
or intermediate affinity binders. This is indicative of the
importance of inclusion these in the search for epitopes
within shared TAAs.
Thus, the inspected proteins indeed contain targets for T
cell reactivity. Further research will include functional
testing of peptide specific T cell cultures to validate the
peptides as true T cell epitopes through demonstration of
intracellular processing and presentation at the cell surface.
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Background: The role of specific components of the
immune systemduring initiation and progression of arthritis
can be studied using various mouse models. Establishing
mouse models with different genetic modifications is a
powerful way to test the function of the modified genes, but
this the process is costly and time consuming. Enforced
expression of Hox homeodomain transcription factors pro-
motes the expansion of hematopoietic stem cells and can be
used generate an unlimited source of immune cell precursors.
CRISPR/Cas9 can be used to rapidly genetically modify
these precursor cells, and the behavior of the modified cells
can then be followed as they develop into mature immune
cells both in vitro and in vivo.
Methods: Mouse hematopoietic stem cells were immor-
talized by retroviral delivery of Hox genes. These precursor
cells were selected and transferred to irradiated mice.
Reconstitution by the precursor cells was followed for
several weeks. Results: A retroviral construct encoding a
fusion protein of the estrogen binding domain and several
different Hox genes was generated and virus particles were
produced. Mouse bone marrow cells were infected with
these constructs resulting in conditionally immortalize
hematopoietic precursor cells. These cells have potential to
differentiate into myeloid and lymphoid cells when
transferred to irradiated mice. The next step is to modify
these precursor cells using CRISPR/Cas9 and then transfer
them to arthritic and wild type mice. This could be used to
rapidly test the function of specific genes for the patho-
genesis of arthritis.
Conclusion: This is a simple and unique method to
immortalize mouse bone marrow cells to generate
hematopoietic progenitor cell lines which can be modified
and differentiated to committed progenitors upon stimuli.
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Myeloid-derived suppressor cells (MDSCs) are immuno-
suppressive regulators in the tumor microenvironment and
are associated with adverse clinical outcomes in most
cancers. Here, we study the effect of the tumor suppressor
Semaphorin3A (SEMA3A) on MDSCs by employing lenti-
viral mediated overexpression of SEMA3A in a mouse
mammary carcinoma model. We show a decreased infil-
tration of gMDSCs in SEMA3A overexpressing tumors
compared to controls. Moreover, gMDSCs derived from
SEMA3A tumor bearing mice show induced levels of the
pro-inflammatory cytokines CCL2, CCL5, CXCL9,
CXCL10 and CXCL11 and decreased levels of MDSC
induced gene S100A9. Interestingly, by depleting the
gMDSCs, we revert the SEMA3A mediated tumor growth
inhibition. We have previously shown that SEMA3A, via
macrophages, recruits cytotoxic lymphocytes to the tumor
microenvironment. Here, our preliminary data show a
trend toward a mechanism whereby the more pro-
inflammatory gMDSCs in SEMA3A overexpressing tumors
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